Search results for "Dara"

showing 10 items of 111 documents

Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results

2019

Abstract Background FLT3-ITD mutations occur in about 25% of patients (pts) with acute myeloid leukemia (AML) and are associated with poor outcomes. Pts with relapsed/refractory (R/R) FLT3-ITD AML have worse prognosis and high unmet medical need. Quizartinib (Q) is a potent and selective FLT3i with promising activity and a manageable safety profile. QuANTUM-R was a global, phase 3, randomized trial of Q vs chemotherapy (SC) in pts with R/R FLT3-ITD AML (NCT02039726). Methods Pts with R/R FLT3-ITD AML w/wo hematopoietic stem cell transplant (HSCT) were randomized to receive Q or a preselected investigator choice SC: low-dose cytarabine; mitoxantrone, etoposide, and intermediate-dose cytarabi…

Oncologymedicine.medical_specialtyMitoxantronebusiness.industryHematologyFludarabineTransplantationchemistry.chemical_compoundOncologychemistryhemic and lymphatic diseasesInternal medicinemedicineCytarabineIdarubicinMidostaurinbusinessEtoposidemedicine.drugQuizartinibAnnals of Oncology
researchProduct

The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.

2008

Despite proven antitumor activity of gemcitabine in chemoradiotherapy of advanced head and neck cancer, many authors refer to severe acute and late local and haematological toxicity. Fludarabine does imply nearly the same mechanisms of action as gemcitabine, inhibiting various enzymes involved in DNA replication. This investigation focuses on the combined effect of either fludarabine or gemcitabine and radiation on human squamous carcinoma cell lines in vitro, providing data for future decisions on head and neck chemoradiotherapy regimen.ZMK-1, A549, BW-225, GR-145, OH-65 and CaSki cell lines were incubated with either drug at defined schedules and irradiated at a single fraction dose of 2 …

Oncologymedicine.medical_specialtyRadiation-Sensitizing AgentsCell SurvivalApoptosisDeoxycytidine03 medical and health sciences0302 clinical medicineFludarabine monophosphateInternal medicineCell Line TumormedicineCarcinomaHumansRadiology Nuclear Medicine and imaging030304 developmental biology0303 health sciencesRadiological and Ultrasound Technologybusiness.industryHead and neck cancermedicine.diseaseGemcitabineGemcitabine3. Good healthFludarabineSquamous carcinomaApoptosis030220 oncology & carcinogenesisCarcinoma Squamous CellbusinessVidarabine PhosphateChemoradiotherapymedicine.drugInternational journal of radiation biology
researchProduct

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

2010

Patients with hematologic diseases who are being treated with therapy drugs, or receive radiation therapy or blood transfusions may develop a host of potentially fatal infectious and noninfectious pulmonary complications [1]. The increased complexity of multimodality and high-dose treatment regimens with the intended benefit of augmented antineoplastic efficacy and prolonged disease-free survival, the use of a panel of novel drugs to treat malignant and nonmalignant hematologic conditions (e.g., azacytidine, bortezomib, cladribine, dasatinib, fludarabine, imatinib, lenalidomide, rituximab, and thalidomide), total body irradiation (TBI) and hematopietic stem cell transplantation (HSCT) have …

Oncologymedicine.medical_specialtybusiness.industryBortezomibTotal body irradiationFludarabineDasatinibTransplantationThalidomidehemic and lymphatic diseasesInternal medicinemedicineRituximabbusinessLenalidomidemedicine.drug
researchProduct

Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Chi…

2014

Abstract Introduction: Mixed chimerism (MC) and minimal residual disease (MRD) strongly predict risk for relapse in children with acute lymphoblastic leukemia (ALL) following allogeneic stem cell transplantation (allo-SCT). Preemptive immunotherapy (IT), e.g. withdrawal of immunosuppression (WD-IS) or donor lymphocyte infusion (DLI) guided by chimerism and MRD monitoring can prevent impending relapse in allo-SCT recipients. In this study we retrospectively analyzed chimerism and MRD monitoring and the effect of preemptive IT in all pts undergoing allo-SCT for ALL in our institution. Patients: Between January 2005 and July 2014, a total of 89 children and adolescents (median age 11.5; range …

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyThioTEPASingle Centermedicine.diseaseBiochemistryMinimal residual diseaseDonor lymphocyte infusionFludarabineSurgeryTransplantationhemic and lymphatic diseasesInternal medicineAcute lymphocytic leukemiamedicineCumulative incidencebusinessmedicine.drugBlood
researchProduct

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Pat…

2019

BACKGROUND: Older patients with acute myeloid leukaemia (AML) who are unsuitable for standard induction therapy have limited treatment options. While DNMT3A, TET2, IDH1/2 and TP53 mutations have been previously associated to better response to hypomethylating agents, there are no molecular biomarkers for low-dose cytarabine (LDAC)-based regimens. AIMS: To predict outcome in AML older patients at diagnosis based on mutation status in the context of FLUGAZA trial. FLUGAZA trial was focus on >65 years AML de novo patients comparing azacytidine vs. fludarabine and LDAC (FLUGA Scheme). METHODS: We analyzed bone marrow (BM) samples at diagnosis from 209 out of 285 AML patients treated accordin…

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyAzacitidineLow dose cytarabineMyeloid leukemiaCell BiologyHematologymedicine.diseaseBiochemistryFludarabineLeukemiamedicine.anatomical_structureInternal medicinemedicineCytarabineBone marrowbusinessNeoadjuvant therapymedicine.drug
researchProduct

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

2017

Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory multiple myeloma (RRMM) remains a challenge; the rational choice of the most appropriate regimen in this setting is currently undefined. We performed a systematic review and 2 standard pairwise meta-analyses to evaluate the efficacy of regimens that have been directly compared with bortezomib or immunomodulatory imide drugs (IMiDs) in head-to-head clinical trials and a network meta-analysis (NMA) to determine the relevance of each regimen on the basis of all the available direct and indirect evidence. Sixteen trials were included in the pairwise meta-analyses, and 18 trials were included…

Oncologymedicine.medical_specialtylenalidomidePharmacologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineMultiple myelomaLenalidomideLymphoid Neoplasiabusiness.industryBortezomibDaratumumabHematologymedicine.diseaseClinical trialmultiple myelomaRegimennetwork meta-analysiTolerability030220 oncology & carcinogenesisbusinessdaratumumab bortezomib030215 immunologymedicine.drugBlood advances
researchProduct

Microanalytical method for studying paintings by use of fluorescence spectroscopy combined with principal component analysis

2013

Abstract The study of several different naturally aged films of organic painting materials, is described. Materials studied include drying oils (walnut, poppy seed and linseed oil) resin-based paint varnishes (the triterpenoid dammar and the diterpenoids sandarac and turpentine) and protein-based binding media (egg yolk and casein). A not expensive methodology for a rapid identification of binding media and varnishes, that applies principal component analysis (PCA) to Excitation Emission (EE) fluorescence spectra, is proposed. PCA was performed on a data matrix where the rows represent studied materials and columns the variables; the variables include the fluorescence intensities associated…

PCAPaintingChromatographyfood.ingredientChemistryOil paintingVarnishSandaracAnalytical chemistryPoppy seedFluorescenceSettore CHIM/12 - Chimica Dell'Ambiente E Dei Beni CulturaliFluorescence spectroscopyAnalytical ChemistryPaintingMicroanalytical methodfoodLinseed oilvisual_artBinding mediavisual_art.visual_art_mediumSettore CHIM/01 - Chimica AnaliticaFourier transform infrared spectroscopySpectroscopyMicrochemical Journal
researchProduct

Semisynthesis of the Antiviral Abietane Diterpenoid Jiadifenoic Acid C from Callitrisic Acid (4-Epidehydroabietic Acid) Isolated from Sandarac Resin

2014

The semisynthesis of the antiviral abietane diterpenoid (+)-jiadifenoic acid C starting from the available methyl ester of callitrisic acid (4-epidehydroabietic acid) isolated from sandarac resin is reported. A protocol for the isolation of methyl callitrisate (methyl 4-epidehydroabietate) in gram quantities from sandarac resin is also described. Allylic C-17 oxygenation was introduced by regioselective dehydrogenation of the isopropyl group of methyl callitrisate with DDQ followed by selenium-catalyzed allylic oxidation. Ester hydrolysis afforded (+)-jiadifenoic acid C in 22% overall yield from methyl callitrisate. This semisynthetic route provides a convenient source of this anti-Coxsacki…

PharmacologyAllylic rearrangementNatural productMolecular StructureChemistryOrganic ChemistrySandaracPharmaceutical ScienceRegioselectivityAntiviral AgentsSemisynthesisTerpenoidEnterovirus B HumanAnalytical Chemistrychemistry.chemical_compoundComplementary and alternative medicineAbietanesDrug DiscoveryMolecular MedicineOrganic chemistryNuclear Magnetic Resonance BiomolecularOxidation-ReductionResins PlantIsopropylAbietaneJournal of Natural Products
researchProduct

Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes

2010

Contrast agents based on dextran-coated superparamagnetic iron oxide nanoparticles (SPIO) are internalized by professional phagocytes such as hepatic Kupffer cells, yet their role in phagocyte biology remains largely unknown. Here we investigated the effects of the SPIO ferucarbotran on murine Kupffer cells and human macrophages. Intravenous injection of ferucarbotran into mice led to rapid accumulation of the particles in phagocytes and to long-lasting increased iron deposition in liver and kidneys. Macrophages incorporate ferucarbotran in lysosomal vesicles containing α-glucosidase, which is capable of degrading the carboxydextran shell of the ferucarbotran particles. Intravenous injectio…

Programmed cell deathMaterials sciencePhagocyteKupffer Cellsmedicine.medical_treatmentIntracellular SpaceBiophysicsApoptosisBioengineeringProinflammatory cytokineBiomaterialsMiceEdaravonemedicineAnimalsHumansMacrophageMagnetite Nanoparticleschemistry.chemical_classificationPhagocytesReactive oxygen speciesTumor Necrosis Factor-alphaDextransFree Radical ScavengersMagnetic Resonance ImagingCell biologyKineticsmedicine.anatomical_structureCytokineLiverchemistryBiochemistryMechanics of MaterialsApoptosisCeramics and CompositesNanoparticlesTumor necrosis factor alphaLysosomesReactive Oxygen SpeciesAntipyrineBiomaterials
researchProduct

Arabinose nucleoside triphosphates are no inhibitors for DNA-dependent RNA polymerases.

1976

1-Beta-D-arabinofuranosylcytosine-5' -triphosphate and 9-beta-D-arabinofuranosyladenosine-5' -triphosphate were found to have no inhibitory potency for both mammalian DNA-dependent RNA polymerase II and E. coli DNA-dependent RNA polymerase.

RNA-dependent RNA polymeraseRNA polymerase IIOviductsCytosine NucleotidesQuailCellular and Molecular Neurosciencechemistry.chemical_compoundAdenosine TriphosphateTranscription (biology)RNA polymeraseRNA polymerase IEscherichia coliAnimalsMolecular BiologyPolymerasePharmacologybiologyChemistryMusclesCytarabineRNACell BiologyDNA-Directed RNA PolymerasesMolecular biologyKineticsAvian Sarcoma VirusesRNA editingbiology.proteinMolecular MedicineRNA Polymerase IIVidarabineExperientia
researchProduct